ProMIS Neurosciences to Participate in Upcoming Conferences in June
Rhea-AI Summary
ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and biotech conferences in June 2026, including Jefferies, Wolfe Research’s Virtual Alzheimer’s R&D Day, Oppenheimer CNS Summit, H.C. Wainwright Neuro Perspectives, and BIO International.
CEO Neil Warma will present the EpiSelect™ platform, lead Alzheimer’s candidate PMN310, and timelines for PRECISE-AD Phase 1b data.
Positive
- None.
Negative
- None.
News Market Reaction – PMN
In the May 28 session, PMN gained 3.77%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 results & funding | Positive | -1.8% | Reported Q1 2026 results, PIPE financing up to $175M and cash runway through 2027. |
| Apr 13 | Investor conference | Positive | +2.5% | Invitation to Bloom Burton investor conference and update on PRECISE-AD Phase 1b timelines. |
| Mar 25 | FY 2025 results | Positive | -9.1% | Full-year 2025 results, completed PRECISE-AD enrollment and $75.5M upfront financing for runway. |
| Mar 18 | Scientific data posters | Positive | -13.0% | AD/PD 2026 posters on ALS and Parkinson’s vaccine and antibody programs targeting misfolded proteins. |
| Feb 04 | Biotech summit participation | Neutral | -16.3% | Participation in Guggenheim biotech summit with fireside chat and one-on-one investor meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the last five news events, shares often declined following generally positive or neutral updates, with only one conference-related announcement seeing a positive 24-hour reaction.
Over the past six months, ProMIS news has centered on financing, trial progress, and conference visibility. Earnings updates on Mar 25, 2026 and May 12, 2026 highlighted completion of enrollment in the PRECISE-AD Phase 1b trial, planned interim analyses, and funding expected to last through 2027, yet shares fell after both. Multiple conference and scientific presentation announcements on Feb 4, Mar 18, and Apr 13 led to mixed price reactions. Today’s June conference schedule extends this pattern of investor outreach tied to PMN310 and neurodegenerative programs.
Key Terms
phase 1b medical
amyloid-beta oligomers medical
biomarker medical
disease modifying therapies medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
Conference details below:
Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.
Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.m. ET (invitation-only)
The event will feature leading companies and key opinion leaders in Alzheimer’s disease research, discussing the current treatment landscape, development of disease modifying therapies and symptom management.
Oppenheimer CNS Summit, June 10, 2026
Location: Miami, FL
One-on-one meetings only
H.C. Wainwright Neuro Perspectives Expert Summit, June 15-16, 2026
Location: New York, NY
Presentation: Monday, June 15, 2026
BIO International Convention, June 22-25, 2026
Location: San Diego, CA
One-on-one meetings only
During these conferences, Neil Warma, CEO of ProMIS Neurosciences, will discuss the Company’s EpiSelect™ platform and differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, including its lead Alzheimer’s disease (AD) candidate, PMN310.
PMN310 is designed to selectively target toxic amyloid-beta oligomers believed to drive AD pathology while avoiding plaque binding, an approach intended to potentially reduce off-target effects associated with plaque-directed therapies.
ProMIS expects to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with 12-month topline data anticipated in early 2027.
Webcast replays of the presentations will be available in the Investors section of the ProMIS Neurosciences website at https://www.promisneurosciences.com/ under “News & Events”.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Forward-looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “anticipates”, “believes”, or variations of such words and phrases. Specifically, this news release contains forward-looking information relating to the Company’s Phase 1b study in AD patients, including planned timing for completion and anticipated data read out of interim results expected in early third quarter of 2026 and topline results by early 2027, statements relating to the Company's progress, including enrollment and dosing, the potential for PMN310 to positively benefit patients with AD, the targeting of toxic misfolded proteins, and the ability of the Company’s cash runway to fund operations through 2027. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks and uncertainties, including the risk that preclinical results or early results may not be indicative of future results. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information.
Investor Relations Contact:
Carie Pierce VP, Investor Relations & External Affairs
IR@promisneurosciences.com
